Viva Biotech Holdings (VB0) - Net Assets
Based on the latest financial reports, Viva Biotech Holdings (VB0) has net assets worth €3.91 Billion EUR (≈ $4.57 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€6.88 Billion ≈ $8.05 Billion USD) and total liabilities (€2.98 Billion ≈ $3.48 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Viva Biotech Holdings to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.91 Billion |
| % of Total Assets | 56.77% |
| Annual Growth Rate | 63.02% |
| 5-Year Change | 1.58% |
| 10-Year Change | N/A |
| Growth Volatility | 192.71 |
Viva Biotech Holdings - Net Assets Trend (2016–2024)
This chart illustrates how Viva Biotech Holdings's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Viva Biotech Holdings for the complete picture of this company's asset base.
Annual Net Assets for Viva Biotech Holdings (2016–2024)
The table below shows the annual net assets of Viva Biotech Holdings from 2016 to 2024. For live valuation and market cap data, see market value of Viva Biotech Holdings.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €3.82 Billion ≈ $4.46 Billion |
+3.48% |
| 2023-12-31 | €3.69 Billion ≈ $4.31 Billion |
+2.31% |
| 2022-12-31 | €3.60 Billion ≈ $4.21 Billion |
-7.89% |
| 2021-12-31 | €3.91 Billion ≈ $4.58 Billion |
+4.17% |
| 2020-12-31 | €3.76 Billion ≈ $4.39 Billion |
+111.37% |
| 2019-12-31 | €1.78 Billion ≈ $2.08 Billion |
+606.88% |
| 2018-12-31 | €251.44 Million ≈ $293.96 Million |
+64.60% |
| 2017-12-31 | €152.76 Million ≈ $178.59 Million |
+99.68% |
| 2016-12-31 | €76.50 Million ≈ $89.44 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Viva Biotech Holdings's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1764.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €4.09 Billion | 107.53% |
| Total Equity | €3.80 Billion | 100.00% |
Viva Biotech Holdings Competitors by Market Cap
The table below lists competitors of Viva Biotech Holdings ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shyft Group Inc
NASDAQ:SHYF
|
$439.02 Million |
|
Hana Tour
KO:039130
|
$439.31 Million |
|
Fujian Oriental Silver Star Investment Co Ltd
SHG:600753
|
$439.46 Million |
|
Beijing ZEHO Waterfront Ecological Environment Treatment Co Ltd
SHG:605069
|
$439.58 Million |
|
First Business Financial Services
NASDAQ:FBIZ
|
$438.75 Million |
|
Sweco AB (publ)
ST:SWEC-A
|
$438.69 Million |
|
Nanjing Res In of Surveying Mapping
SHE:300826
|
$438.66 Million |
|
Guangzhou Tech-Long Packing Machine Co Ltd
SHE:002209
|
$438.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Viva Biotech Holdings's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,687,912,000 to 3,802,377,000, a change of 114,465,000 (3.1%).
- Net income of 167,294,000 contributed positively to equity growth.
- Share repurchases of 23,019,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €167.29 Million | +4.4% |
| Share Repurchases | €23.02 Million | -0.61% |
| Other Changes | €-29.81 Million | -0.78% |
| Total Change | €- | 3.10% |
Book Value vs Market Value Analysis
This analysis compares Viva Biotech Holdings's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.10x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.75x to 0.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.10 | €0.18 | x |
| 2018-12-31 | €0.17 | €0.18 | x |
| 2019-12-31 | €1.14 | €0.18 | x |
| 2020-12-31 | €1.97 | €0.18 | x |
| 2021-12-31 | €2.04 | €0.18 | x |
| 2022-12-31 | €1.88 | €0.18 | x |
| 2023-12-31 | €1.72 | €0.18 | x |
| 2024-12-31 | €1.80 | €0.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Viva Biotech Holdings utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.42%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.85x
- Recent ROE (4.40%) is below the historical average (12.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 31.99% | 25.36% | 0.95x | 1.33x | €16.82 Million |
| 2017 | 49.92% | 51.44% | 0.73x | 1.32x | €60.98 Million |
| 2018 | 36.01% | 43.11% | 0.40x | 2.11x | €65.41 Million |
| 2019 | 14.96% | 82.30% | 0.17x | 1.07x | €88.13 Million |
| 2020 | -10.30% | -55.51% | 0.09x | 2.17x | €-762.56 Million |
| 2021 | 7.35% | 13.67% | 0.26x | 2.06x | €-103.79 Million |
| 2022 | -14.66% | -22.21% | 0.30x | 2.20x | €-888.95 Million |
| 2023 | -3.15% | -5.39% | 0.29x | 2.02x | €-484.90 Million |
| 2024 | 4.40% | 8.42% | 0.28x | 1.85x | €-212.94 Million |
Industry Comparison
This section compares Viva Biotech Holdings's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,057,695,497
- Average return on equity (ROE) among peers: -39.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Viva Biotech Holdings (VB0) | €3.91 Billion | 31.99% | 0.76x | $439.02 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $243.06 Million | -74.97% | 0.23x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $209.51 Million | -46.30% | 0.68x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $2.05 Billion |
| BioNTech SE (22UA) | $11.89 Billion | 86.54% | 0.33x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $3.43 Billion | -0.21% | 0.03x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.56 Billion | -20.91% | 0.36x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such a… Read more